ArticleBlood neoplasia2026
ctDNA for MRD assessment is prognostic and predictive in newly diagnosed and relapsed/refractory lymphoma.
Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating tumor DNA (ctDNA) is a novel biomarker to assess tumor burden, molecular residual disease (MRD), and treatment response in various cancers. To our knowledge, this study reports the largest real-world cohort to date evaluating ctDNA testing, ctDNA-MRD detection, and ctDNA clearance dynamics in newly diagnosed and relapsed/refractory lymphoma. We analyzed plasma from 144 patients with stage I to IV primary lymphoma (aggressive B-cell lymphoma, n = 110; aggressive T-cell lymphoma, n = 13; indolent B-cell lymphoma, n = 15; indolent T-cell lymphoma, n = 6; median, 7 samples per patient). ctDNA was evaluated using a personalized, tumor-informed, multiplex polymerase chain reaction assay (Signatera). Pretreatment ctDNA was detectable in 92% of the evaluable patients. End-of-treatment (EOT) ctDNA-MRD positivity was prognostic of inferior event-free survival (EFS; adjusted hazard ratio [HR], 22.43; 95% confidence interval [CI], 6.76-74.45;
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.